Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Payables (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Payables data on record, last reported at $3.5 million in Q4 2025.

  • For Q4 2025, Payables rose 19.73% year-over-year to $3.5 million; the TTM value through Dec 2025 reached $3.5 million, up 19.73%, while the annual FY2025 figure was $3.5 million, 19.73% up from the prior year.
  • Payables reached $3.5 million in Q4 2025 per AMLX's latest filing, down from $5.3 million in the prior quarter.
  • Across five years, Payables topped out at $24.7 million in Q2 2023 and bottomed at $1.5 million in Q3 2024.
  • Average Payables over 5 years is $8.7 million, with a median of $6.3 million recorded in 2022.
  • Peak YoY movement for Payables: tumbled 86.68% in 2024, then skyrocketed 259.05% in 2025.
  • A 5-year view of Payables shows it stood at $4.4 million in 2021, then surged by 43.12% to $6.3 million in 2022, then soared by 252.58% to $22.1 million in 2023, then crashed by 86.68% to $2.9 million in 2024, then grew by 19.73% to $3.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $3.5 million in Q4 2025, $5.3 million in Q3 2025, and $3.3 million in Q2 2025.